In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

Sang Hoon Lee,1 Daniel Lopes de Menezes,1 Jayesh Vora,2 Alex Harris,3 Helen Ye,1 Lara Nordahl,1 Evelyn Garrett,1 Emil Samara,2 Sharon Lea Aukerman,1 Arnold B. Gelb,1 and Carla Heise1

Abstract

Purpose: To evaluate the therapeutic and biological effects of CHIR-258, an orally bioavailable, potent inhibitor of class III-V receptor tyrosine kinases, in colon cancer models.

Experimental Design: The pharmacologic activity of CHIR-258 was characterized by monitoring target modulation as well as by evaluating the antitumor and antiangiogenic effects in human colon xenograft models.

Results: CHIR-258 inhibits vascular endothelial growth factor receptor 1/2, fibroblast growth factor receptor 1/3, and platelet-derived growth factor receptor β (PDGFRβ) and shows both antitumor and antiangiogenic activities in vivo. Treatment of KM12L4a human colon cancer cells with CHIR-258 resulted in a dose-dependent inhibition of vascular endothelial growth factor receptor 1 and PDGFRβ phosphorylation and reduction of phosphorylated extracellular signal-regulated kinase (ERK) levels, indicating modulation of target receptors and downstream signaling. In vivo administration of CHIR-258 resulted in significant tumor growth inhibition and tumor regressions, including large, established tumors (500-1,000 mm3). Immunohistochemical analysis showed a reduction of phosphorylated PDGFRβ and phosphorylated ERK in tumor cells after oral dosing with CHIR-258 compared with control tumors. These changes were accompanied by decreased tumor cell proliferation rate and reduced intratumoral microvessel density. CHIR-258 inhibited the phosphorylation of PDGFRβ and ERK phosphorylation in tumors within 2 hours following dosing and the inhibitory activity was sustained for >24 hours. Significant antitumor activity was observed with intermittent dosing schedules, indicating a sustained biological activity.

Conclusion: These studies provide evidence that biological activity of CHIR-258 in tumors correlates with efficacy and aids in the identification of potential biomarkers of this multitargeted receptor tyrosine kinase inhibitor. CHIR-258 exhibits properties that make it a promising candidate for clinical development in a variety of solid and hematologic malignancies.

Cancer is the result of a multistep process of genomic alterations, including mutations in key regulatory proteins that result in loss of balanced gene expression and subsequent malignant transformation. Receptor tyrosine kinases (RTK) are mediators of cellular proliferation and mutations are often associated with hyperplasia and tumor development (1–3). These transmembrane RTKs contain an extracellular domain for ligand binding and intracellular kinase domains that mediate autophosphorylation, recruitment of downstream signaling molecules, and signal transduction. There are >30 RTKs implicated in cancer, including the type III [platelet-derived growth factor receptor (PDGFR), colony-stimulating factor receptor, FMS-like tyrosine kinase 3, and KIT], type IV [fibroblast growth factor receptor (FGFR) 1-4], and type V [vascular endothelial growth factor receptor (VEGFR) 1-3] RTKs. RTK overexpression and/or activating mutations are often present in tumor cells and are implicated in tumor growth and progression of both solid and hematologic malignancies. For example, glioblastoma proliferation can be driven by overexpression of PDGFR, melanoma by VEGFR, and small cell lung cancer by KIT (4–9). In addition, a constitutively active mutation of KIT is associated with gastrointestinal stromal tumors (6, 10), and FMS-like tyrosine kinase 3 mutations are associated with disease progression in acute myelogenous leukemia (11, 12). Chromosomal translocations resulting in acquisition of PDGFR and FGFR activating mutations have been identified in chronic myelogenous monocyte leukemia and multiple myeloma, respectively (9, 13). In addition to their direct function in induction or maintenance of tumorigenesis, several RTKs, such as VEGFR, FGFR, and PDGFR, also play major roles in tumor angiogenesis, a process essential for growth of tumors (14, 15). In particular, VEGFR1-2 and FGFR1 on endothelial cells are activated by

www.aacrjournals.org
Clin Cancer Res 2005;11(10) May 15, 2005 3633

Cancer is the result of a multistep process of genomic alterations, including mutations in key regulatory proteins that result in loss of balanced gene expression and subsequent malignant transformation. Receptor tyrosine kinases (RTK) are mediators of cellular proliferation and mutations are often associated with hyperplasia and tumor development (1–3). These transmembrane RTKs contain an extracellular domain for ligand binding and intracellular kinase domains that mediate autophosphorylation, recruitment of downstream signaling molecules, and signal transduction. There are >30 RTKs implicated in cancer, including the type III [platelet-derived growth factor receptor (PDGFR), colony-stimulating factor receptor, FMS-like tyrosine kinase 3, and KIT], type IV [fibroblast growth factor receptor (FGFR) 1-4], and type V [vascular endothelial growth factor receptor (VEGFR) 1-3] RTKs. RTK overexpression and/or activating mutations are often present in tumor cells and are implicated in tumor growth and progression of both solid and hematologic malignancies. For example, glioblastoma proliferation can be driven by overexpression of PDGFR, melanoma by VEGFR, and small cell lung cancer by KIT (4–9). In addition, a constitutively active mutation of KIT is associated with gastrointestinal stromal tumors (6, 10), and FMS-like tyrosine kinase 3 mutations are associated with disease progression in acute myelogenous leukemia (11, 12). Chromosomal translocations resulting in acquisition of PDGFR and FGFR activating mutations have been identified in chronic myelogenous monocyte leukemia and multiple myeloma, respectively (9, 13). In addition to their direct function in induction or maintenance of tumorigenesis, several RTKs, such as VEGFR, FGFR, and PDGFR, also play major roles in tumor angiogenesis, a process essential for growth of tumors (14, 15). In particular, VEGFR1-2 and FGFR1 on endothelial cells are activated by
VEGF or basic fibroblast growth factor secreted by tumor cells and stromal cells, resulting in proliferation, migration, and survival of tumor endothelial cells (3, 15–17). PDGFRβ is expressed on pericytes, smooth muscle cells, and stromal cells and is involved in pericyte recruitment and vessel maturation during tumor angiogenesis and PDGF-BB is expressed in several stromal cell types (18–22).

The increased understanding of the molecular pathways responsible for oncogenesis, angiogenesis, and tumor progression have led to the development of successful mechanism-based cancer therapies. Throughout the various stages of colon cancer, complex genetic alterations occur, of which overexpression of growth factors, such as VEGF, FGF, and PDGF and their corresponding RTKs, have been shown to correlate with invasiveness, tumor angiogenesis, metastasis, recurrence, and poor prognosis of colorectal cancer (23–27). Because colorectal cancer is the third most common cancer and third leading cause of death due to cancer in both men and women in the United States, a therapeutic agent that inhibits these RTKs has the potential to be a broadly effective therapy through both antitumor and antiangiogenic mechanisms. Such targeted agents are expected to be better tolerated than chemotherapeutic agents, because they affect characteristics often unique to the cancer cells and/or soluble factors associated with tumor survival. Several of these agents have been approved by the Food and Drug Administration (e.g., imatinib, trastuzumab, gefitinib, cetuximab, and bevazicipumab) and many others are in clinical trials. Bevacizumab, a recombinant humanized monoclonal antibody to VEGF, which inhibits tumor angiogenesis, showed a significant increase in survival of patients with metastatic colorectal cancer when used in combination with standard chemotherapy compared with standard chemotherapy alone (28–30). Cetuximab, an antibody against the epidermal growth factor receptor, is marketed for treatment of patients with advanced, metastatic colorectal cancer. Several small molecule inhibitors that target multiple RTKs (SU5416, SU6668, SU11248, CP-547,632, and PTK-787/ZK222584) have also been shown to inhibit tumor growth and angiogenesis in preclinical models of colon cancers (31–35). PTK-787/ZK222584, an inhibitor of VEGFR, is now in phase III trials for colorectal cancer.

CHIR-258 is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Because CHIR-258 simultaneously targets RTKs expressed in tumor cells, stromal cells, endothelial cells, and pericytes, it is expected to exhibit antitumor efficacy by both direct and indirect mechanisms. In this report, we provide data characterizing the combined antiangiogenic and antitumor activity of CHIR-258 in murine human colon xenograft models. Inhibition of tumor cell proliferation and reduction of intratumoral microvessel density were observed after treatment with CHIR-258 in vivo. The pharmacologic activity of CHIR-258 was evaluated by monitoring the in vivo inhibition of its target RTKs and downstream signaling molecules in tumor tissues. Plasma exposures necessary for target modulation and antitumor efficacy were also determined. These data indicate that CHIR-258 has potent antitumor and antiangiogenic activities that are associated with target modulation and biological activity in vivo, characteristics necessary for a potentially successful clinical therapy.

Materials and Methods

Chemical synthesis. CHIR-258 [4-amino-5-fluoro-3-[6-(4-methyl-1-piperaziny1)-1H-benzimidazol-2-yl]-2(1H)-quinolinone], with a molecular weight of 392.4, was synthesized at Chiron Corp. (Emeryville, CA).

Tumor cell lines. The human colon cancer cell lines used for these studies were KM12L4a and HCT116. KM12L4a cells were obtained from Dr. I. Fidler (M.D. Anderson Cancer Center, Houston, TX) and cultured in EMEM supplemented with 10% fetal bovine serum, 200 mmol/L L-glutamine, and 100 mmol/L sodium pyruvate (Life Technologies, Inc., Gaithersburg, MD). HCT116 cells were obtained from American Type Culture Collection (Bethesda, MD). HCT116 cells were obtained from American Type Culture Collection (Bethesda, MD) and cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mmol/L L-glutamine (Life Technologies). Reverse transcription-PCR evaluation indicated that KM12L4a human colon cancer cells express VEGFR1/2 and PDGFRβ, and HCT116 cells were positive for VEGFR1, PDGFRβ, and FGFR1. For studies of target modulation in vitro, KM12L4a human colon cells were cultured in 10% serum-containing medium and incubated with CHIR-258 for 3 hours.

In vivo studies. Female nude mice (6–8 weeks old, 18–22 g) were obtained from Charles River Laboratories (Wilmington, MA). Animals received sterile rodent chow and water ad libitum and were housed in a barrier facility in sterile filter-top cages with 12-hour light/dark cycles. All experiments were conducted in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International and in accordance with all guidelines of the Institutional Animal Care and Use Committee and the Guide for the Care and Use of Laboratory Animals (National Research Council). Tumor cells (2 × 10⁵ KM12L4a or 5 × 10⁵ HCT116) were implanted s.c. into the flank of mice and allowed to grow to the specified size before treatment was initiated. CHIR-258 solution was formulated in water and was given orally on either daily or intermittent administration schedules as outlined in the individual experimental design (see below). Tumors were measured twice to thrice weekly using bilateral caliper measurements and volumes (mm³) were calculated using the following formula: 1/2 [length × (width²)]. Percent tumor growth inhibition (TGI) was determined as [1 – (mean tumor volume of each CHIR-258-treated dose group / mean tumor volume of vehicle-treated group)] × 100.

Pharmacokinetics in KM12L4a tumor-bearing mice. Tumor-bearing mice were treated with 10, 30, or 100 mg/kg CHIR-258 once daily for 22 days. Blood samples were collected at 2, 8, and 24 hours on day 2 (n = 2 mice per time point per dose group). Pre-dose (trough) samples were collected on days 3, 8, and 15 (n = 2–3 mice per time point per dose group). Plasma was separated by centrifugation and stored frozen (−70°C) until analysis. Plasma samples (10 μL) were protein precipitated by addition of acetonitrile (150 μL; mixed, and centrifuged and the supernatant was evaporated on a warm plate. The residue was reconstituted in 0.1% formic acid/20% methanol and mixed and 10 μL were injected into a liquid chromatograph with tandem mass spectrometry (Sciex API 3000). The liquid chromatography system consisted of PE Series 200 micro pumps and Waters Xterra C18 column (15 × 2 mm). Samples were eluted using a gradient between 1% formic acid in water and 1% formic acid in acetonitrile. The column eluant was ionized through a TurboIon spray and quantitated by tandem mass spectrometry. This qualified assay showed a lower limit of quantitation of 1 ng/mL and a calibration range of 1 to 8,000 ng/mL. The average concentration-time data within each dose group was subjected to pharmacokinetic analysis using standard noncompartmental methods (36). Cmax values were reported as observed. Area under plasma concentration-time curve was calculated from time 0 to time of last quantifiable concentration using trapezoidal rule. Trough concentrations were reported from samples collected immediately before dosing on days 2, 3, 8, and 15.

Target modulation in vivo. Single-dose studies were conducted to assess in vivo target modulation. Animals with established tumors (~200–300 mm³, n = 4–5 per group) were given a single oral dose of...
of CHIR-258. Mice bearing KM12L4a tumors were given 10, 30, or 100 mg/kg CHIR-258 and tumor samples were collected at 0, 2, 4, 24, 48, and 72 hours post-dose. Mice bearing HCT116 tumors were given 100 mg/kg CHIR-258 and tumor samples were collected at 0, 1, 2, 4, 24, and 48 hours post-dose.

**Immunoprecipitation and Western blot.** Target modulation by CHIR-258 was evaluated in vitro and in vivo. Cells and excised tumor xenografts were lysed in radioimmunoprecipitation assay buffer [150 mmol/L NaCl, 10 mmol/L Tris-HCl (pH 7.2), 0.1% SDS, 1% Triton X-100, 1% deoxycholate, and 5 mmol/L EDTA] containing protease inhibitors (Roche Molecular Biochemicals, Indianapolis, IN) and phosphatase inhibitors (Sigma, St. Louis, MO). PDGFRs, FGFR1, VEGFR1, and VEGFR2 were immunoprecipitated from equal amounts of protein with antibodies against each receptor (Santa Cruz Biotechnology, Santa Cruz, CA) and protein phosphorylation was analyzed with anti-phosphotyrosine 4G10 antibody (Upstate, Mountain View, CA). To insure equal loading and transfer efficiency, Western blots were reprobed with antibodies against total PDGFRβ, FGFR1, VEGFR1, and VEGFR2. To evaluate the effect of CHIR-258 on levels of phosphorylated extracellular signal-regulated kinase (p-ERK), Western blot analysis was done from total lysates using an antibody against p-ERK (Cell Signaling Technology, Beverly, MA) and total ERK level was evaluated by rehybridizing with an antibody against total ERK protein (Cell Signaling Technology). The X-ray films were scanned and the level of phosphorylation was determined by densitometry.

**Vascular endothelial growth factor ELISA.** Mice bearing KM12L4a tumors were given 10, 30, or 100 mg/kg CHIR-258 daily for 5 days and tumors were excised 4 hours post-dose on day 5. Tumors (n = 3 per group) were lysed in radioimmunoprecipitation assay buffer containing protease inhibitors and phosphatase inhibitors. VEGF-A protein in tumor lysates was quantified by ELISA (R&D Systems, Minneapolis, MN). Protein concentration of each sample was determined using Bio-Rad (Hercules, CA) protein assay reagent, and VEGF levels were normalized to protein concentrations.

**Immunohistochemistry.** Tissue sections fixed in 10% neutral buffered formalin overnight at room temperature. The tissues were then placed in 70% ethanol and subsequently processed for paraffin embedding using a Thermo Electron Excelsior tissue processor (Pittsburgh, PA). Tissue sections (4 μm) were stained using a Discovery automated slide staining system (Ventana Medical Systems, Tucson, AZ). Tissue sections (4 μm) were stained using an antibody against total ERK (Cell Signaling Technology), in a dose-dependent manner with an IC90 value <50 nmol/L. In addition, CHIR-258 also inhibited phosphorylation of ERK in KM12L4a cells following by immunoprecipitation and Western blot analysis. As shown in Figure 1, CHIR-258 inhibited the phosphorylation of VEGFR1 and PDGFRβ in a dose-dependent manner with an IC90 value <50 nmol/L. In addition, CHIR-258 also inhibited phosphorylation of ERK, a downstream signaling molecule of RTKs, in a dose-dependent manner with an IC90 value <50 nmol/L. These data indicate that CHIR-258 inhibits the activity of its target receptors in KM12L4a tumor cells and results in down-modulation of the signaling pathway.

**Results**

**In vitro kinase activity**

The in vitro activity of CHIR-258 was determined using biochemical and cell-based kinase assays. Biochemical kinase assays showed potent and selective inhibition of class III-V RTKs (Table 1). VEGFR kinases were inhibited with IC50 values of <14 nmol/L, PDGFRβ at 27 nmol/L, and FGFR1 at 8 nmol/L.

**CHIR-258 inhibits vascular endothelial growth factor receptor 1 and platelet-derived growth factor receptor β phosphorylation in vivo**

Reverse transcription-PCR and immunoprecipitation indicated that KM12L4a human colon cancer cells express VEGFR1/2 and PDGFRβ, and HCT116 human colon cells express VEGFR1, PDGFRβ, and FGFR1. To investigate the ability of CHIR-258 to inhibit VEGFR1 and PDGFRβ kinase activity, KM12L4a cells were incubated with varying concentrations of CHIR-258 in vitro followed by immunoprecipitation and Western blot analysis. As shown in Figure 1, CHIR-258 inhibited the phosphorylation of VEGFR1 and PDGFRβ in a dose-dependent manner with an IC90 value <50 nmol/L. In addition, CHIR-258 also inhibited phosphorylation of ERK, a downstream signaling molecule of RTKs, in a dose-dependent manner with an IC90 value <50 nmol/L. These data indicate that CHIR-258 inhibits the activity of its target receptors in KM12L4a tumor cells and results in down-modulation of the signaling pathway.

**Pharmacokinetics of CHIR-258 in KM12L4a tumor-bearing mice**

The plasma pharmacokinetics of CHIR-258 were determined in KM12L4a tumor-bearing mice following once-daily oral dosing of increasing doses of CHIR-258. Previous studies with CHIR-258 in mice showed that the terminal elimination t1/2 in plasma was ~3 hours at all doses tested. Plasma CHIR-258 concentrations increased with dose across the dose range evaluated (Table 2). Plasma Cmax values increased from 163 ng/mL (10 mg/kg) to 742 ng/mL (30 mg/kg) to 1,560 ng/mL (100 mg/kg). Correspondingly, area under plasma concentration-time curve values increased from 1,420 ng h/mL (10 mg/kg) to 5,540 ng h/mL (30 mg/kg) to 18,300 ng h/mL (100 mg/kg).

---

### Table 1. Kinase selectivity of CHIR-258

<table>
<thead>
<tr>
<th>RTK</th>
<th>Kinase IC50 (nmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FMS-like tyrosine kinase 3</td>
<td>1</td>
</tr>
<tr>
<td>KIT</td>
<td>2</td>
</tr>
<tr>
<td>VEGFR1</td>
<td>10</td>
</tr>
<tr>
<td>VEGFR2</td>
<td>13</td>
</tr>
<tr>
<td>VEGFR3</td>
<td>8</td>
</tr>
<tr>
<td>FGFR1</td>
<td>8</td>
</tr>
<tr>
<td>FGFR3</td>
<td>9</td>
</tr>
<tr>
<td>PDGFRβ</td>
<td>27</td>
</tr>
<tr>
<td>Colony-stimulating factor receptor</td>
<td>36</td>
</tr>
<tr>
<td>PDGFRα</td>
<td>200</td>
</tr>
<tr>
<td>INSR</td>
<td>2,100</td>
</tr>
<tr>
<td>Epidermal growth factor receptor 1</td>
<td>2,218</td>
</tr>
<tr>
<td>ErbB2</td>
<td>&gt;20,000</td>
</tr>
<tr>
<td>Raf</td>
<td>&gt;25,000</td>
</tr>
</tbody>
</table>

---

(100 mg/kg). Trough concentrations were low (2-4 ng/mL) after the 10 mg/kg dose but ranged from 7 to 23 ng/mL after 30 mg/kg and from 50 to 135 ng/mL after 100 mg/kg.

A single dose of CHIR-258 results in target modulation in vivo

To evaluate the onset and duration of target modulation in vivo, single-dose studies were done in HCT116 and KM12L4a tumor-bearing mice. HCT116 tumors were collected pre-dose and at 1, 2, 4, 24, and 48 hours following one oral dose of 100 mg/kg CHIR-258. As shown in Fig. 2, a significant inhibition of p-ERK was observed at 2 hours post-dose and maintained for up to 24 hours post-dose. By 48 hours, p-ERK levels returned to baseline.

To evaluate the effects of both dose and time on target modulation, KM12L4a tumor tissues were collected at pre-dose and at 2, 4, 24, 48, and 72 hours after administration of 10, 30, or 100 mg/kg CHIR-258 (Table 3; Fig. 3). Within 2 hours of dosing, PDGFRβ phosphorylation was inhibited by 57% to 62% at all doses of CHIR-258 evaluated. Further reduction in target modulation was observed at 4 hours (inhibition by 76-82% versus pre-dose) and remained similar at all doses evaluated. Target inhibition was maintained (40-50% inhibition) through 24 hours with 30 and 100 mg/kg but not at the 10 mg/kg dose. Similarly, p-ERK expression was significantly inhibited at 2 and 4 hours post-dose of 10, 30, or 100 mg/kg and was maintained (~50%) at 24 hours with 30 and 100 mg/kg of CHIR-258. The levels of p-PDGFR and p-ERK returned to baseline in each dose group by 48 hours post-dose.

Growth inhibition and regression of human colon tumor xenografts by CHIR-258

Dose-response studies. To evaluate the antitumor efficacy of CHIR-258, daily oral doses from 3 to 100 mg/kg were given to mice bearing s.c. KM12L4a or HCT116 human tumor xenografts.
Treatment was initiated when tumors reached 125 to 200 mm$^3$ (Fig. 4A). Potent antitumor activity was seen in both KM12L4a and HCT116 tumor models and a significant dose-dependent inhibition of tumor growth was observed within 4 to 7 days of treatment initiation. Tumor regressions from 50% to 100% of initial size were observed in some tumors at doses >60 mg/kg. The minimal effective dose (resulting in ~50% TGI) was 10 mg/kg/d in both tumor models. Percent TGI was calculated relative to vehicle-treated tumors.

**Antitumor activity in late-stage, large tumors.** To determine whether CHIR-258 treatment could result in tumor regression or stabilization of large tumors, daily oral dosing of CHIR-258 was initiated when the KM12L4a tumors reached 500 or 1,000 mm$^3$ and continued daily for 25 days. Treatment with 60 or 120 mg/kg/d induced tumor regression and/or stabilization in 35 of 37 tumor-bearing mice (Fig. 4B). Tumor growth was statistically significantly inhibited at both dose levels as early as 4 days post-treatment initiation. The maximum TGI for the 60 and 120 mg/kg dose levels (initial tumor volume of 500 mm$^3$) was 81% and 85%, respectively. The maximum inhibition for the 60 and 120 mg/kg doses with initial tumor volumes of 1,000 mm$^3$ was 69% and 79%, respectively. CHIR-258 produced regressions (25-99% shrinkage) as well as stable disease (~25% of initial tumor volume) in this established tumor model. On day 25, the combined results at 60 mg/kg for each initial tumor size were 32% tumor regression, 58% stable disease, and 10% with progressive disease ($n = 19$). The 120 mg/kg treatments resulted in 88% regressions and 12% with stable disease ($n = 18$).

**Antitumor activity with intermittent dosing of CHIR-258.** Several alternate dosing regimens were explored to evaluate the antitumor activity of CHIR-258. Every other day (100 or 150 mg/kg every other day for 30 days) or intermittent administration (100 mg/kg/d on days 1-5, 18-22, and 26-30) of CHIR-258 to KM12L4a tumor-bearing mice resulted in significant tumor shrinkage (Fig. 4C). Alternate daily dosing with either of the two doses resulted in initial tumor responses or stabilization in all tumors. With 150 mg/kg given every other day, one tumor completely regressed and five of the remaining seven tumors were partial responses (50-99% reduction from initial size). At the 100 mg/kg dose, seven of eight tumors regressed up to 80% of initial volume and one remained stable in volume. The intermittent schedule began with five daily doses of 100 mg/kg/d after which tumors were 60% to 80% of the initial size. Tumors continued to regress or stabilize for 5 to 10 days during the “drug holiday” (days 6-17) and then began to regrow but were responsive to the second cycle of treatment. In a separate study in animals bearing HCT116 tumors, 100 mg/kg CHIR-258 given cyclically for 5 days on and 5 days off for 25 days (i.e., days 1-5, 11-15, and 21-25) were as effective as 70 mg/kg dose once daily for 25 days (data not shown).

![Table 3. Target modulation by CHIR-258 in KM12L4a tumors](https://www.aacrjournals.org/clinres/article-pdf/11/10/3637/6581256/clincancerres-11-10-03637.pdf)
These in vivo tumor efficacy studies show that CHIR-258 treatment results in potent tumor growth inhibitory effects, including responses in very large tumors. The antitumor activity was also observed with intermittent dosing regimens, demonstrating that the biological effects of CHIR-258 were sustained even during “the drug holiday” period when plasma concentrations were not quantifiable. This observation may permit greater flexibility in selection of dosing regimens for future clinical trials.

CHIR-258 antitumor activity is associated with target modulation and biological activity in vivo

To investigate the mechanistic effects of antitumor activity, immunohistochemistry and ELISA assays were done to evaluate changes in tumors after treatment with CHIR-258. KM12L4a tumors were removed after seven daily doses of 100 mg/kg CHIR-258 or vehicle to assess histopathologic changes and immunohistochemical localization of target modulation within the tumor. CHIR-258 resulted in a significant reduction of
phosphorylated PDGFRβ on tumor cells (Fig. 5A and B). Immunohistochemical detection of ERK phosphorylation in control tumors was moderate to strong in the majority of tumor cells, whereas after CHIR-258 treatment p-ERK stain was only localized to isolated focal areas (Fig. 5C and D). These results confirm the immunoprecipitation/Western blot data in tumor lysates and show that target modulation is further potentiated after multiple doses of CHIR-258. Actively dividing tumor cells were identified by immunostaining with an antibody against Ki67, and CHIR-258-treated tumors showed a significant reduction of Ki67-positive staining, indicating inhibition of tumor cell proliferation (Fig. 5E and F). Large areas of necrosis were also evident in CHIR-258-treated tumors when compared with vehicle-treated tumors. To evaluate the antiangiogenic activity of CHIR-258 in vivo, an anti-CD31 antibody was used to visualize tumor vasculature. CHIR-258 treatment resulted in a decrease of both number and size of CD31-positive vessels within the tumors (Fig. 5G and H). CHIR-258 treatment resulted in a visually apparent decrease in both number and size of CD31-positive vessels within the tumors (Fig. 5G and H). Quantification by computerized image analysis confirmed a 65% decrease in mean relative vessel area (expressed as a percentage) with 7 days of CHIR-258 treatment (0.96 ± 0.14) compared with vehicle (0.34 ± 0.13), but group sizes were small and statistical significance was not reached. This reduction in microvessel density in tumors supports the antiangiogenic activity of CHIR-258 as has been shown previously in vitro and in vivo.5

Additionally, we observed a dose-dependent reduction in VEGF production in tumors as determined by ELISA on the tumor homogenates collected after 5 days of dosing with 10, 30, or 100 mg/kg CHIR-258. Treatment with 30 mg/kg inhibited VEGF production by ~35%, whereas 100 mg/kg treatment resulted in decreased levels of VEGF by ~66%. There was no change in tumor VEGF levels with 10 mg/kg CHIR-258 (Fig. 6).

Discussion

Growth factors and the activation of their cognate receptors play a pivotal role in oncogenic and survival pathways of tumors and in angiogenesis (1, 3, 37, 38). Small molecule inhibitors are being developed as an approach for the therapeutic blockade of kinase signaling in cancer. The notable success of the targeted agent imatinib (STI571, Gleevec) represents a promising strategy for the development of anticancer therapies (39–42). Additionally, the clinical success of bevacizumab (Avastin) has validated the idea that blocking angiogenesis is an effective strategy to treat human cancer (43, 44). Further evidence that RTKs are considered valuable targets for cancer therapy include the recent Food and Drug Administration approval of the epidermal growth factor receptor inhibitor gefitinib (Iressa) and the promising early clinical results verification of multityargeted kinase inhibitors, such as SU11248, BAY 43-9006, and PTK-787 (40, 45–47). Because most cancers rarely depend on a single growth factor or genetic alteration for initiation and progression, targeting multiple RTKs is a strategy for interfering with the complex signaling pathways of cancer cells.

The goal for early clinical development of oncology therapies is to determine the optimal dose and schedule of administration of the drug. This has traditionally been based on toxicity end points (particularly for cytotoxic agents) and pharmacokinetic-safety relationships. More recently, development strategies...
for molecular targeted therapies have included studies to identify patients most likely to respond through evaluation of expression and activation of the targets and evaluation of biological activity after treatment using pharmacodynamic assays. Pharmacodynamic end points may aid in defining a pharmacologically active dose based on optimal target modulation in phase I studies. One approach for clinical evaluation of RTK and signal transduction pathway inhibitors is to examine pharmacodynamic changes in target activation in tumor or surrogate tissues. In addition, the concurrent evaluation of plasma exposure with target modulation and efficacy in preclinical studies may potentially facilitate identification of ‘effective’ plasma exposures in patients and guide dose and dosing selection in phase I studies.

In studies reported here, we have described the antitumor, antiangiogenic, and target modulation activity of CHIR-258, a multitargeted small molecule RTK inhibitor. The antitumor and antiangiogenic effects of this compound are due to its inhibition of class III-V RTKs, notably the VEGFR, FGFR, and PDGFR families. CHIR-258 inhibited the autophosphorylation of its target RTKs in a dose-dependent manner in human colon tumor cells in vitro and in vivo. Consistent with the ability to block RTK phosphorylation, CHIR-258 was also able to inhibit phosphorylation of ERK, a downstream signaling molecule of RTKs. Tumor regression and stabilization in colon tumor models were observed at dose levels (30-100 mg/kg) consistent with those required for target modulation. This antitumor activity could be, therefore, correlated with the ability of CHIR-258 to inhibit its target RTKs and downstream signaling molecules important for proliferation and/or survival of the cellular components of tumors.

The dose and time dependency of p-PDGFR and p-ERK inhibition in vivo with CHIR-258 was shown in the KM12L4a colon tumor model. All doses tested resulted in target modulation at 2 and 4 hours post-dose. A dose of 10 mg/kg (minimally efficacious) showed a duration of inhibition of phosphorylation <24 hours, whereas efficacious doses (30-100 mg/kg) resulted in durable target modulation throughout a 24-hour period after dosing. Patterns of inhibition of the phosphorylation of PDGFRβ and ERK were similar.

Although the degree of inhibition of PDGFR and ERK phosphorylation was similar after a single dose of 30 or 100 mg/kg, there were clear differences in the corresponding antitumor effects. Doses of 30 mg/kg resulted in TGI in the KM12L4a model, whereas 100 mg/kg/d was associated with tumor stasis or tumor regression. This suggests that PDGFR inhibition itself is not the sole factor in TGI in the model or that downstream activities after RTK inhibition contribute to the longer-term effects associated with tumor regression. In addition, the higher plasma exposures of CHIR-258 after a 100 mg/kg dose, relative to those after a 30 mg/kg dose, may also account for this difference in antitumor activity. For example, a more pronounced effect on tumor vascularization was seen by immunostaining at the 100 mg/kg dose compared with the 30 mg/kg dose (data not shown) and there was a clear dose-dependent reduction in VEGF production within the tumor after CHIR-258 treatment.

Recent studies indicated that the combination of inhibiting both VEGF and PDGFB signaling pathways provides added benefits for antiangiogenic therapy (48, 49). Pericyte recruitment by tumor vasculature and maintenance of tumor blood vessels is primarily dependent on PDGFBβ signaling, whereas VEGF induces the new vessel growth; thus, the inhibition of both pathways potently disrupts tumor vasculature and induces tumor regression. PDGFBβ is expressed on KM12L4a tumor cells as well as on pericytes and other stromal cells. Our data suggest that CHIR-258 is active against the KM12L4a tumor cells directly as well as the stroma and endothelial cells, thus supporting the antitumor and antiangiogenic activity of CHIR-258 in this tumor model.

Sustained inhibition of proliferation and survival signals is necessary for durable TGI and regression. Immunostaining with antibodies against Ki67 showed significant reduction in tumor cell proliferation after CHIR-258 treatment. The prolonged effects of CHIR-258 were evident in studies using intermittent dosing schedules. Tumors continued to regress or were stabilized in growth during periods of dosing holidays, indicating a sustained biological effect in the absence of continuous exposure to CHIR-258. Mechanistic studies with tumors removed up to 5 days after cessation of dosing indicate induction of cell cycle arrest and apoptosis (data not shown).

These findings indicate that RTK inhibition with CHIR-258 resulted in durable in vivo biological activity that translated into significant antitumor effects. Dose scheduling studies showed tumor regression or stasis with alternate daily dosing and for up to 7 days after discontinuation of daily dosing. These observations should aid the clinical development of CHIR-258 as well as providing further support for the development of targeted therapies with multiple specificities against RTKs implicated in growth and survival of solid tumors.

Acknowledgments

We thank Bahija Jallal, Dirk Mendel, Joe Carlino, and Jon Williams for helpful scientific discussions and comments on the article, Paul Renhowe and Marion Wiesmann for contributions, and Gavin Dollinger and Keshi Wang for expert assistance in bioanalytical analyses.

References

11. Gilliland DG. Molecular genetics of human leukemias:

www.aacrjournals.org
In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

Sang Hoon Lee, Daniel Lopes de Menezes, Jayesh Vora, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/11/10/3633

Cited articles
This article cites 46 articles, 14 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/11/10/3633.full.html#ref-list-1

Citing articles
This article has been cited by 24 HighWire-hosted articles. Access the articles at:
/content/11/10/3633.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.